Aim Immunotech Inc. · AMEX:AIM
Aim Immunotech — Investor Presentation (May 2021)
18 slides from Aim Immunotech's investor presentation, May 18, 2021
Slide 1: Company Presentation May 2021
Company Presentation May 2021
Slide 2: Forward-Looking Statements
Forward- Looking Statements AIM ImmunoTech - Company Presentation - May 2021 Some of the statements included in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Among other things, for those statements, we claim the protection of safe harbor for f
Slide 3: AIM ImmunoTech
AIM ImmunoTech AIM ImmunoTech - Company Presentation - May 2021 We are an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of viral diseases, cancers, and immune- deficiency disorders. AIM’s flagship products are Ampligen (rintatolimod) and Alfero
Slide 4: Product Pipeline
Product Pipeline Ampligen is being studied in clinical settings with human subjects in the United States and the European Union. Additionally, it is approved as a treatment for ME/CFS in Argentina. AIM ImmunoTech - Company Presentation - May 2021 +Cancer with COVID-19 - In combination w/Interferon A
Slide 5: Ampligen - Mechanism of Action
Ampligen - How can a single drug work on botha Mec h a nis m of broad spectrum of viruses and a broad e spectrum of tumor types? Action AIM ImmunoTech - Company Presentation - May 2021
Slide 6: Ampligen is an immuno-modulator working through TLR3 pathways
pinpligen is an immuno-modulator that can help the body mount a potentially broad-spectrum immune i reporee through the toll-like receptor 3 (TLR3) pathways, which are among the primary pathways for antiviral protection. Q: How cana 3 [ d cant sl aoe pet baat prey ona ngs. Instead, it works through
Slide 7: Ampligen is a selective activator of the TLR3 pathway
Ampligen is a selective activator of the TLR3 pathway that has great potential as a single-agent therapeutic and may potentially enhance the performance of checkpoint inhibitors, and the drug’s “mechanism of action” appears ideally suited to boost the efficacy of Q: How cana PD-1 and PD-L1 checkpoin
Slide 8: Ampligen and COVID-19: Potential prophylaxis for first responders
» Ampligen is a broad-spectrum antiviral. Am pl igen and > In animal studies, Ampligen demonstrated complete protection (100% survival) against SARS-CoV-1, Ebola virus, Western Equine COVID-19: Encephalitis virus and Herpes Simplex virus. Potential » The SARS-CoV-2 virus - the cause of the ongoing C
Slide 9: AIM's Current COVID-19 Efforts
AIM’s Current COVID-19 Efforts AIM ImmunoTech - Company Presentation - May 2021 AIM is working with Roswell Park Comprehensive Cancer Center on a Phase 1/2 clinical trial of Ampligen (clinicaltrials.gov/NCT04379518) to test the safety and effectiveness of Ampligen to clear the SARS-CoV-2 virus from
Slide 10: Ampligen in ME/CFS
Ampligen in ME/CFS AIM ImmunoTech - Company Presentation - May 2021 > Based upon Phase 2 and 3 clinical trial data, AIM received commercial approval for Ampligen in the treatment of severe ME/CFS in Argentina in 2016. In a PLOS ONE journal article published October 29, 2020, AIM researchers found th
Slide 11: Ampligen and COVID-Induced Chronic Fatigue: Long COVID
Ampligen and COVID-Induced Chronic Fatigue: Long COVID or ‘Long Haulers’ AIM ImmunoTech - Company Presentation - May 2021 COVID-19 is triggering a large number of CFS-like cases The high number of younger people being hospitalized for COVID-19 suggests considerable numbers of people in the prime of
Slide 12: AIM ImmunoTech - Company Presentation - May 2021
AIM ImmunoTech - Company Presentation - May 2021
Slide 13: Early Access Program with Ampligen in Late-Stage Pancreatic Cancer
Early Access Program (EAP) with Ampligen as a Treatment in Late- Stage Pancreatic Cancer Shows Statistically Significant Increased Overall Survival Compared to Historical Controls AIM ImmunoTech - Company Presentation - May 2021 Site: Erasmus University, The Netherlands, conducted by Professor Caspe
Slide 14: AIM's Next Steps for Pancreatic Cancer Therapy Development
» Proposed Phase 2 Follow-up Study ’ » Develop a protocol design and schema AIM S Next in consultation with Buffet Cancer Center and Erasmus Medical Center Steps for » Develop a full protocol with Amarex Py Clinical Research and obtain Pa ncreatic regulatory approval to initiate a Phase 2 clinical t
Slide 15: Lag ~OLC Lal Lance ME g Ne Li
Lag ~OLC Lal Lance ME g Ne Li arly-5 DE Ff Stal ( GS AIM ImmunoTech - Company Presentation - May 2021
Slide 16: AIM's corporate headquarters and facilities
AIM’s corporate headquarters is in Ocala, Fla. The company also owns and operates a 30,000 sq. ft. facility in New Brunswick, N.J., and is in the process of updating the manufacturing and laboratory suites. re Yimn hology tora bettey PU tL AIM ImmunoTech - Company Presentation - Nay 2021 4
Slide 17: Key Statistics
Key Statistics NYSE American: AIM Share Price (5/14/21) Shares Outstanding (5/14/21) Market Cap (5/14/21) Cash, Cash Equivalents & Marketable Securities (3/31/21) As of 5/14/21, AIM had zero debt $2.01 47.8M $96.1 M $63.6M 17
Slide 18: Executive Management Team
Executive Management Team > Thomas K. Equels, M.S., J.D. / Chief Executive Officer - Equels was named Chief Executive Officer in February 2016 and has served as President since August 2015. Equels’ successful legal career included extensive experience in the pharma sector. He has over the years serv